The study was terminated due to slow accrual of subjects.

The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.

Inclusion Criteria:

• Signed written informed consent
• Age ≥ 18 years
• Patients with confirmed solid tumor and scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosage and schedule in the study.
• Experienced thrombocytopenia as evidenced by a platelet count < 100 Gi/L in the preceding cycle immediately before study enrollment.
• ECOG performance status ≤ 2
• For females, surgically sterilized, postmenopausal or agree to use an acceptable form of birth control
• Patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib, trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by the investigator and after consultation and approval from the Sponsor
• PT/INR and aPTT are within 80% to 120% of the normal range

Exclusion Criteria:

• Experienced thrombocytopenia as evidenced by a platelet count < 25 Gi/L at any time in the preceding cycle immediately before enrollment into the study
• History or presence of clinically significant disease
• Received any TRAs, or rHuIL-11 within the last 4 weeks prior to screening
• Had received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening).
• Pregnant, wanting to become pregnant or lactating